The past year has witnessed a substantial contribution from Indian investigators to the global rheumatology landscape. From biologic and targeted therapies in axial spondyloarthritis and rheumatoid arthritis to immunologic predictors of infection in lupus, thrombotic mechanisms in antiphospholipid syndrome, and the economic burden of chronic autoimmune disease, Indian cohorts are providing clinically meaningful data with real-world relevance. This article summarizes key highlights from recently published and presented Indian studies.

Expanding Therapeutic Options in Axial Spondyloarthritis

 A retrospective analysis ⁽¹⁾ evaluated the efficacy and safety of an adalimumab biosimilar in patients with axial spondyloarthritis (axSpA) treated at a tertiary centre in South India. The study demonstrated significant clinical improvement in disease activity indices over follow-up, with an acceptable safety profile. Importantly, treatment persistence and response rates were comparable to historical data from originator biologics, supporting the growing role of biosimilars in improving affordability without compromising effectiveness in resource-constrained settings.

Complementing biologic therapy, long-term data on tofacitinib presented at ACR convergence⁽²⁾ highlighted sustained efficacy in active axSpA. Patients showed durable improvements in inflammatory back pain, functional outcomes, and inflammatory markers over extended follow-up. Safety findings were consistent with established JAK inhibitor profiles, without unexpected signals. These findings reinforce the place of oral targeted synthetic DMARDs as viable alternatives for patients who are biologic-naïve or intolerant.

Optimizing Rheumatoid Arthritis Management

In rheumatoid arthritis, a randomized double-blind placebo-controlled study⁽³⁾ evaluated iguratimod in combination with background methotrexate. The trial demonstrated superior clinical response rates compared with placebo, along with acceptable tolerability. Improvements were noted in composite disease activity measures and inflammatory biomarkers, suggesting that iguratimod may offer an effective adjunct option in Indian patients with inadequate methotrexate response.

Further addressing disease trajectory, a tertiary-care experience⁽⁴⁾ from northern India examined palindromic rheumatism and predictors of progression to RA. Seropositivity for rheumatoid factor and anti-CCP antibodies, along with persistent synovitis, emerged as key predictors. Early identification of high-risk individuals may allow timely intervention and possibly disease modification.

Immunogenicity and Infection Risk in Autoimmune Disease

Vaccination outcomes in autoimmune diseases remain a priority. A cohort study ⁽⁵⁾assessed SARS-CoV-2 vaccine–induced humoral and cell-mediated immune responses in Indian patients with RA. While most patients mounted adequate antibody responses, those receiving certain immunosuppressants demonstrated attenuated titres. Encouragingly, T-cell responses were relatively preserved in many cases, supporting vaccination while highlighting the need for individualized booster strategies.

In systemic lupus erythematosus (SLE), investigators from the INSPIRE cohort ⁽⁶⁾reported that baseline antibodies to type I and type III interferons predisposed patients to serious infections during follow-up. This novel observation suggests that interferon-neutralizing autoantibodies may identify a subset of lupus patients at heightened infection risk, potentially informing monitoring and prophylactic strategies.

Antiphospholipid Syndrome: Beyond Classical Thrombosis

Emerging work in antiphospholipid syndrome has broadened understanding of thrombotic and renal complications. One study⁽⁷⁾ identified elevated plasminogen activator inhibitor-1 (PAI-1) levels as a contributor to increased thrombotic risk, suggesting a mechanistic link between impaired fibrinolysis and clinical events. This insight may open avenues for risk stratification beyond traditional antiphospholipid antibody profiles.

Another single-centre cohort⁽⁸⁾ focused on renal involvement in primary APS. Histologic findings ranged from thrombotic microangiopathy to chronic vascular lesions, with certain patterns predicting poorer renal outcomes. Recognizing APS nephropathy as a distinct entity is critical, as it may require tailored therapeutic strategies beyond standard anticoagulation.

Inflammatory Myopathies and Vasculitis: Clinical Outcomes

An analysis of acute-onset inflammatory myositis described clinical characteristics and survival outcomes in an Indian cohort⁽⁹⁾. Early aggressive disease, especially with respiratory involvement, was associated with worse prognosis. Prompt recognition and intensive immunosuppression were emphasized as key determinants of survival.

Long-term safety of extended rituximab therapy in ANCA-associated vasculitis (AAV) was examined in a prospective multicentre study⁽¹⁰⁾. Maintenance regimens demonstrated sustained remission with manageable adverse events, supporting prolonged B-cell depletion in carefully selected patients. These data contribute to the evolving maintenance paradigm in AAV management.

Juvenile Rheumatology and Diagnostic Nuances

A pediatric case series⁽¹¹⁾ from South India highlighted conditions mimicking juvenile idiopathic arthritis (JIA), including progressive pseudorheumatoid dysplasia and CACP syndrome. Misdiagnosis may lead to unnecessary immunosuppression. The study emphasized detailed clinical evaluation, radiographic assessment, and genetic testing in atypical or treatment-refractory cases.

Transcriptomics and Remission in Reactive Arthritis

Transcriptomic profiling in reactive arthritis⁽¹²⁾ revealed enrichment of Enterobacteriaceae-related pathways in synovial fluid and peripheral blood. Interestingly, specific gene signatures were associated with subsequent drug-free remission. These findings strengthen the hypothesis that microbial triggers and host immune responses jointly influence disease course, and that molecular signatures could eventually guide prognostication.

The Economic Burden of Rheumatic Disease in India

Beyond clinical outcomes, two major studies have addressed the financial impact of chronic rheumatic illness. A multicentre cross-sectional study ⁽¹³⁾examined catastrophic health expenditure in Indian patients with SLE. A substantial proportion of families experienced severe financial strain, particularly those requiring hospitalization or advanced therapies. Predictors included disease severity, rural residence, and lack of comprehensive insurance coverage.

Similarly, another research⁽¹⁴⁾ evaluated the economic repercussions of RA in Karnataka. Direct medical costs, productivity loss, and out-of-pocket expenses contributed to high rates of catastrophic expenditure. The findings underscore the urgent need for policy reforms, expanded insurance coverage, and cost-effective therapeutic strategies.

Conclusion: Integrating Science, Safety, and Sustainability

Collectively, these studies reflect the maturing landscape of Indian rheumatology research. Biosimilars and targeted therapies are expanding access while maintaining efficacy. Immunologic insights are refining risk prediction in lupus and APS. Molecular profiling and novel diagnostics promise more personalized care. At the same time, the persistent economic burden reminds clinicians and policymakers that therapeutic advances must be paired with equitable healthcare delivery.

As India continues to generate high-quality clinical and translational data, these contributions will not only inform local practice but also enrich global rheumatology knowledge. The integration of innovation, vigilance in safety, and sensitivity to socioeconomic realities will define the next chapter in advancing care for patients with rheumatic diseases.

References:

1. Gopalan A, Gavali M, Yerram K. Efficacy & safety of adalimumab biosimilar in axial spondyloarthritis: A retrospective study from a tertiary care centre in South India. The Indian Journal of Medical Research. 2025 Dec 31;162(5):670.
2. https://acrabstracts.org/abstract/long-term-efficacy-and-safety-of-tofacitinib-in-active-axial-spondyloarthritis-experience-from-a-tertiary-care-center-in-south-india/
3. https://acrabstracts.org/abstract/effectiveness-and-safety-of-iguratimod-with-background-methotrexate-therapy-in-indian-patients-with-rheumatoid-arthritis-a-randomized-double-blinded-placebo-controlled-study/
4. https://acrabstracts.org/abstract/palindromic-rheumatism-and-predictors-of-progression-to-rheumatoid-arthritis-experience-from-a-tertiary-care-center-in-northern-india/
5. Swain N, Tripathy A, Sahoo B, Padhan P, Raghav SK, Gupta B. SARS-CoV-2 vaccine induced humoral & cell-mediated immune responses in Indian cohort of rheumatoid arthritis. The Indian Journal of Medical Research. 2025 Dec 8;162(4):520.
6. https://acrabstracts.org/abstract/antibodies-to-type-i-and-type-iii-interferons-at-diagnosis-predispose-to-serious-infections-on-follow-up-in-an-inception-cohort-of-sle-inspire-from-india/
7. https://acrabstracts.org/abstract/plasminogen-activator-inhibitor-1-increases-thrombotic-risk-in-antiphospholipid-syndrome/
8. https://acrabstracts.org/abstract/beyond-thrombosis-histological-spectrum-predictors-and-outcomes-of-renal-involvement-in-primary-antiphospholipid-syndrome-a-single-centre-cohort-study/
9. https://acrabstracts.org/abstract/acute-onset-inflammatory-myositis-clinical-features-and-survival/
10. https://acrabstracts.org/abstract/a-multicenter-prospective-longitudinal-observational-study-to-determine-safety-of-extended-treatment-with-rituximab-in-maintaining-remission-in-patients-with-anca-associated-vasculitis-aav-an-inte/
11. https://acrabstracts.org/abstract/juvenile-idiopathic-arthritis-mimics-a-case-series-on-progressive-pseudo-rheumatoid-dysplasia-and-cacp-syndrome-in-pediatric-patients-from-a-tertiary-center-in-south-india/
12. https://acrabstracts.org/abstract/reactive-arthritis-transcriptomics-enriched-enterobacteriaceae-related-pathways-in-synovial-fluid-and-in-blood-is-associated-with-drug-free-remission/
13. Shobha V, Kishor K, Gera C, Nayana V, Ramteke S, Kayidhi S, Shukla A, Patel N, Subramanian R, Mahabaleshwar M, Jain A. Financial burden of systemic lupus erythematosus in India: prevalence and predictors of catastrophic health expenditure in a multicentre cross-sectional study. BMC rheumatology. 2025 Nov 6;9(1):131.
14. Shobha, V., Singhai, S., Haridas, V. et al. The financial repercussions of rheumatoid arthritis and determinants of catastrophic healthcare expenditure: insights from the Karnataka chapter of the Indian rheumatology association. Health Econ Rev 15, 90 (2025). https://doi.org/10.1186/s13561-025-00680-1